论文部分内容阅读
目的 研究MT在乳腺癌中的表达水平及其与预后的关系。方法 采用免疫组化S -P法 ,检测 91例乳腺癌中MT的表达水平 ,并结合随访资料进行分析。结果 MT主要在细胞核及细胞浆表达 ,癌组织中总阳性率 83 .5 %。MT表达阴性组 3、5年生存率分别为 93 %和 86% ,弱阳性组分别为 88%和 83 % ,阳性组分别为 72 %和 60 % ,强阳性组分别为 62 %和 5 5 % ,差异有显著性 (P <0 .0 5 )。多因素Logistic回归分析提示 ,MT表达具有独立预后价值 ,即表达水平越高 ,预后越差。结论 MT表达水平可作为判断乳腺癌预后的可靠指标。
Objective To study the expression of MT in breast cancer and its relationship with prognosis. Methods Immunohistochemical S-P method was used to detect the expression of MT in 91 cases of breast cancer and the follow-up data were analyzed. Results MT was mainly expressed in nucleus and cytoplasm. The total positive rate of MT was 83.5%. The 3-year and 5-year survival rates of MT-negative group were 93% and 86%, respectively, 88% and 83% for the weakly positive group, 72% and 60% for the positive group and 62% and 55% , The difference was significant (P <0. 05). Multivariate Logistic regression analysis showed that MT expression has an independent prognostic value, that is, the higher the expression level, the worse the prognosis. Conclusion MT expression level can be used as a reliable indicator of breast cancer prognosis.